Please click on the ID to see detailed information about each entry.
| ID | Name | Sequence | Assay | Nature of peptide or cargo | Tissue permeability (value with units) | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1405 | Spantide | rPKPQQwFwLL | Radioimmunoassay, HPLC | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Systemic uptake corresponds to a serum concentration peak of 4.5*10-9M after 15 minutes | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1406 | Spantide | rPKPQQwFwLL | Radioimmunoassay, HPLC | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Systemic uptake corresponds to a serum concentration peak of 1*10-8M after 15 minutes and intraoccular uptake corresponded to a plateau at 140-150ng/ml for 1-3 hours after completion of application | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1407 | Spantide | rPKPQQwFwLL | Radioimmunoassay, HPLC | Effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. | Systemic uptake corresponds to a serum concentration peak of 1*10-7M after 15 minutes and intraoccular uptake corresponded to a plateau at 1.3-1.5µg/ml for 90-240 minutes after completion of application giving an approximate concentration of 10m6 M in the aqueous humor. | Left eye of pigmented rabbits of either sex and weighing 2-3 kg | 1689665 |
| 1408 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=1; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=1.2; where, 0=No corneal pathology; 1=Comeal infiltrate without significant melti | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1409 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=2.2, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting (tw | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1410 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=1/Control=1.2; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=3.1, where, 0=No corneal pathology; 1=Comeal infiltrate without signi | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1411 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting (two- | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1412 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=1.1/Control=2.7; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4, where, 0=No corneal pathology; 1=Comeal infiltrate without signi | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1413 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting (two- | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1414 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=1.2/Control=4.8; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4, where, 0=No corneal pathology; 1=Comeal infiltrate without signi | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1415 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4.2, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting (tw | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1416 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=2.2/Control=5.3; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1/Control=4.9, where, 0=No corneal pathology; 1=Comeal infiltrate without sig | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1417 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=2.7/Control=5.3; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=1.3/Control=4.9, where, 0=No corneal pathology; 1=Comeal infiltrate without s | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1418 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=2/Control=4.9, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting (tw | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1419 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=2.8/Control=4.9, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; 4=Grade III melting ( | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1420 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=4.1/Control=5.6; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=3/Control=4.9, where, 0=No corneal pathology; 1=Comeal infiltrate without sig | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1421 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=4.7/Control=5.6; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=3.5/Control=5, where, 0=No corneal pathology; 1=Comeal infiltrate without sig | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1422 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=4.9/Control=5.8; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=4/Control=5, where, 0=No corneal pathology; 1=Comeal infiltrate without signi | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1423 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=4.8/Control=5.8; Average clinical score according to hours-post inoculation for topically applied bacterial inoculum(treatment till 24 hours post inoculation): Inhibitor=4/Control=5, where, 0=No corneal pathology; 1=Comeal infiltrate without signi | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1424 | Thiol based metalloproteinase inhibitor | FA | Peptidase activity checked via enzyme assay, Clinical evaluation and scoring, Statistical analysis | Potent inhibitor of corneal coliagenase, alkali-induced corneal ulceration and P. aeruginosa elastase | Average clinical score according to hours-post inoculation for topically and subconjunctivally applied bacterial inoculum(treatment till 26 hours post inoculation): Inhibitor=5.2/Control=5.8, where, 0=No corneal pathology; 1=Comeal infiltrate without significant melting; 2=Grade I melting (none to one-third of the corneal surface); 3=Grade II melting (one-third to two-thirds of the corneal surface) and/or mild bulging; | One eye of the New Zealand White rabbits weighing between 2 and 2.5 kg was used as test and the other as control | 2127341 |
| 1425 | Vasoactive intestinal peptide (VIP) | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Tear film osmolarity | Potent cAMP-dependent stimulus of both fluid and protein secretion from the rat and rabbit main lacrimal gland | Osmolarity measurements: t=0 min., VIP/Buffer=330/314.5mOsm/l; t=16 min., VIP/Buffer=315/313.5mOsm/l | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1426 | Vasoactive intestinal peptide (VIP) | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Tear film osmolarity | Potent cAMP-dependent stimulus of both fluid and protein secretion from the rat and rabbit main lacrimal gland | Osmolarity measurements: t=0 min., VIP/Buffer=320/318mOsm/l; t=6 min., VIP/Buffer=303.5/310mOsm/l; t=16 min., VIP/Buffer=310/314mOsm/l | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1427 | Vasoactive intestinal peptide (VIP) | HSDAVFTDNYTRLR KQMAVKKYLNSILN | Osmolarity and tear volume measurements | Potent cAMP-dependent stimulus of both fluid and protein secretion from the rat and rabbit main lacrimal gland | Osmolarity measurements: t=0 min., VIP/Buffer=315/320mOsm/l; t=6 min., VIP/Buffer=301/314mOsm/l; t=16 min., VIP/Buffer=308/313mOsm/l; Volume measurement: VIP/Buffer= 17µl/7µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1428 | Secretin | HSDGTLTSELSRLRD RARLQRLLQGLL | Tear film osmolarity | Secretin stimulates the release of a watery bicarbonate solution from the pancreatic and bile duct epithelium. | Caused decrease in tear film osmolarity | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1429 | Secretin | HSDGTLTSELSRLRD RARLQRLLQGLL | Tear film osmolarity | Secretin stimulates the release of a watery bicarbonate solution from the pancreatic and bile duct epithelium. | Caused decrease in tear film osmolarity | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1430 | Secretin | HSDGTLTSELSRLRD RARLQRLLQGLL | Osmolarity and tear volume measurements | Secretin stimulates the release of a watery bicarbonate solution from the pancreatic and bile duct epithelium. | Caused decrease in tear film osmolarity, Tear volume: VIP/Buffer= 5.0±0.8µl/5.5±0.5µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1431 | Glucagon | HSQGTFTSDYSKYLD SRRAQDFVQWLMNT | Tear film osmolarity | The pancreas releases glucagon when the concentration of glucose in the bloodstream falls too low in order to raise glucose levels | Osmolarity measurements: t=0 min., Glucagon/Buffer=311/312.5mOsm/l; t=6 min., Glucagon/Buffer=304/306.5mOsm/l; t=16 min., Glucagon/Buffer=305/307.5mOsm/l | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1432 | Glucagon | HSQGTFTSDYSKYLD SRRAQDFVQWLMNT | Osmolarity and tear volume measurements | The pancreas releases glucagon when the concentration of glucose in the bloodstream falls too low in order to raise glucose levels | Osmolarity measurements: t=0 min., Glucagon/Buffer=310/308mOsm/l; t=6 min., Glucagon/Buffer=301/306mOsm/l; t=16 min., Glucagon/Buffer=305/307mOsm/l; Volume measurement: Glucagon/Buffer= 11.5µl/5.2µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1433 | α-MSH (α-Melanocyte-stimulating hormone ) | SYSMEHFRWGKPV | Osmolarity and tear volume measurements | It acts as an antagonist to interleukin 1 (IL-1) bioactivities such as inhibition of fever production, thymocyte proliferation, and inhibition of release of acute phase inflammatory molecules from the liver. | Osmolarity measurements: t=0 min., α-MSH/Buffer=310/311mOsm/l; t=6 min., α-MSH/Buffer=301/306mOsm/l; t=16 min., α-MSH/Buffer=305/308mOsm/l; Volume measurement: α-MSH/Buffer= 17.5µl/6.2µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1434 | β-MSH (β-Melanocyte-stimulating hormone) | AEKKDEGPYRMEHFR WGSPPKD | Osmolarity and tear volume measurements | MSH stimulate the production and release of melanin (a process referred to as melanogenesis) by melanocytes in skin and hair. MSH actions in the brain have effects on appetite and sexual arousal. | Osmolarity measurements: t=0 min., β-MSH/Buffer=310/311mOsm/l; t=6 min., β-MSH/Buffer=301.5/306mOsm/l; t=16 min., β-MSH/Buffer=306/308mOsm/l; Volume measurement: β-MSH/Buffer= 14µl/56.1µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1435 | ƴ-MSH (ƴ-Melanocyte-stimulating hormone) | YVMGHFRWDRFG | Osmolarity and tear volume measurements | MSH stimulate the production and release of melanin (a process referred to as melanogenesis) by melanocytes in skin and hair. MSH actions in the brain have effects on appetite and sexual arousal. | Osmolarity measurements: t=0 min., ƴ-MSH/Buffer=311/312.5mOsm/l; t=6 min., ƴ-MSH/Buffer=303/306mOsm/l; t=16 min., ƴ-MSH/Buffer=307/309mOsm/l; Volume measurement: ƴ-MSH/Buffer= 12µl/6µl | Eyes of male and female New Zealand white rabbits with closed lacrimal gland excretory duct | 2365569 |
| 1436 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Intraocular pressure (IOP) calculated electromanometrically, blood-aqueous barrier, pupil size, blood pressure and cyclic AMP (CAMP) content in the aqueous humour of rabbits via 125I-radioimmunoassay | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | IOP:Control=1.8mmHg, Neutral formaldehyde=From the baseline of 16.9±1.5 it rose by 27.3±3.8mmHg in 15.1±1.8 minutes, CGRP(0.5µg)=From the baseline of 18.5±1.1 it rose by 11.8±2.3mmHg in 15.0±2 minutes; Mean arterial blood pressure:Control=94±12/101±10(before), Formaldehyde=92±5/95±3(before), CGRP=94±5/98±4(before); cAMP after 30 minutes:Control=16.3±3.6pmol/ml, Formaldehyde right eye=88.5±35pmol/ml, Formaldehyde left e | Albino rabbits of both sexes weighing 2.2-3.1 kg were used. Right eye=Contralateral eye and left eye=Experimental. | 2842178 |
| 1437 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Intraocular pressure (IOP) calculated electromanometrically, blood-aqueous barrier, pupil size, blood pressure and cyclic AMP (CAMP) content in the aqueous humour of rabbits via 125I-radioimmunoassay | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | IOP:Control=1.8mmHg, Neutral formaldehyde=From the baseline of 16.9±1.5 it rose by 27.3±3.8mmHg in 15.1±1.8 minutes, CGRP(2.0µg)=From the baseline of 17.5±0.9 it rose by 19.3±3.6mmHg in 6.3±1.5 minutes; Mean arterial blood pressure:Control=94±12/101±10(before), Formaldehyde=92±5/95±3(before), CGRP=85±6/104±5(before); cAMP after 30 minutes:Control=16.3±3.6pmol/ml, Formaldehyde right eye=88.5±35pmol/ml, Formaldehyde left | Albino rabbits of both sexes weighing 2.2-3.1 kg were used. Right eye=Contralateral eye and left eye=Experimental. | 2842178 |
| 1438 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Radio-actively labelled microspheres were used to determine blood flow | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Regional blood flow in anterior uvea(iris+ciliary body): For CGRP it rose by 244.8±80.2mg/minute/whole tissue, For saline it rose by 33.8±16.2mg/minute/whole tissue | Eyes of New Zealand albino rabbits | 3262039 |
| 1439 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Radio-actively labelled microspheres were used to determine blood flow | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Regional blood flow in anterior uvea(iris+ciliary body): For CGRP it rose by 244.8±80.2mg/minute/whole tissue, For saline it rose by 33.8±16.2mg/minute/whole tissue, For methysergide it rose by 54.1±23.3mg/minute/whole tissue | Eyes of New Zealand albino rabbits | 3262039 |
| 1440 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Lowry method for protein estimation, cAMP content via 125I-radioimmunoassay, Electromanometrical recording intraocular pressure | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Protein=23.7±2.3mg/ml, cAMP=243.2±37.9pmol/ml, Intraocular pressure=22mmHg at 5 min, 28mmHg at 10 min, 37mmHg at 15 min, 38mmHg at 28 min, 35mmHg at 30 minutes. | Eyes of New Zealand albino rabbits | 3262039 |
| 1441 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Lowry method for protein estimation, cAMP content via 125I-radioimmunoassay, Electromanometrical recording intraocular pressure | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Protein=13.3±6.2mg/ml, cAMP=147.0±7.4pmol/ml, Intraocular pressure=19mmHg at 5 min, 21mmHg at 10 min, 26mmHg at 15 min, 31mmHg at 28 min, 35.5mmHg at 30 minutes. | Eyes of New Zealand albino rabbits | 3262039 |
| 1442 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Lowry method for protein estimation, cAMP content via 125I-radioimmunoassay, Electromanometrical recording intraocular pressure | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Protein=0.6±0.04mg/ml, cAMP=34.6±3.1pmol/ml, Intraocular pressure=18mmHg at 5 min, 17mmHg at 10 min, 16.1mmHg at 15 min, 15.9mmHg at 28 min, 15.5mmHg at 30 minutes. | Eyes of New Zealand albino rabbits | 3262039 |
| 1443 | α-CGRP (α-calcitonin gene-related peptide) | ACDTATCVTHRLAGL LSRSGGVVKNNFVPT NVGSKAF | Lowry method for protein estimation, cAMP content via 125I-radioimmunoassay, Electromanometrical recording intraocular pressure | Specific binding sites for CGRP have been demonstrated both in the brain and in peripheral target tissues, where CGRP has been shown to act through a CAMP-dependent mechanism | Protein=0.6±0.1mg/ml, cAMP=65.3±14.7pmol/ml, Intraocular pressure=14.5mmHg at 5 min, 13mmHg at 10 min, 12.8mmHg at 15 min, 12.5mmHg at 28 min, 13.1mmHg at 30 minutes. | Eyes of New Zealand albino rabbits | 3262039 |
| 1444 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Fluid: Tears- intact peptide=800pmoles/ml fluid, degraded peptide=2250pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=33.7% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1445 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Fluid: Tears- intact peptide=250pmoles/ml fluid, degraded peptide=500pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=59% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1446 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Conjunctiva- intact peptide=135pmoles/g tissue, degraded peptide=172pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=76.7% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1447 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Conjunctiva- intact peptide=175pmoles/g tissue, degraded peptide=185pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=85% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1448 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Conjunctiva- intact peptide=180pmoles/g tissue, degraded peptide=230pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=81.7% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1449 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal epithelium- intact peptide=270pmoles/g tissue, degraded peptide=300pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=86.1% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1450 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal epithelium- intact peptide=655pmoles/g tissue, degraded peptide=710pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=91.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1451 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal epithelium- intact peptide=885pmoles/g tissue, degraded peptide=1120pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=72.1% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1452 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal stroma- intact peptide=28pmoles/g tissue, degraded peptide=31pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=87.9% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1453 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal stroma- intact peptide=81pmoles/g tissue, degraded peptide=92pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=84.2% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1454 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Corneal stroma- intact peptide=37.5pmoles/g tissue, degraded peptide=48pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=96.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1455 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Iris-Ciliary Body- intact peptide=5.2pmoles/g tissue, degraded peptide=6.5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=81.0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1456 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Iris-Ciliary Body- intact peptide=8.3pmoles/g tissue, degraded peptide=9pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=98.1% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1457 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Tissue: Iris-Ciliary Body- intact peptide=4.8pmoles/g tissue, degraded peptide=5.5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=96.8% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1458 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Fluid: Aqueous humor- intact peptide=0.75pmoles/ml fluid, degraded peptide=0.9pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=93.8% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1459 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Fluid: Aqueous humor- intact peptide=5.4pmoles/ml fluid, degraded peptide=5.7pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=99.0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1460 | Leucine enkephalin | YGGFL | Radioactive determination | Leu-enkephalin is an endogenous opioid peptide neurotransmitter that is found naturally in the brains of many animals, including humans. | Fluid: Aqueous humor- intact peptide=5.0pmoles/ml fluid, degraded peptide=5.24pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=99.4% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1461 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Fluid: Tears- intact peptide=850pmoles/ml fluid, degraded peptide=2230pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=84.9% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1462 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Fluid: Tears- intact peptide=500pmoles/ml fluid, degraded peptide=740pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=77.3% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1463 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Conjunctiva- intact peptide=175pmoles/g tissue, degraded peptide=190pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=98.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1464 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Conjunctiva- intact peptide=315pmoles/g tissue, degraded peptide=325pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=99% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1465 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Conjunctiva- degraded peptide=130pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1466 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal epithelium- degraded peptide=350pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=98.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1467 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal epithelium- degraded peptide=550pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=99% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1468 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal epithelium- degraded peptide=875pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1469 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal stroma- intact peptide=25pmoles/g tissue, degraded peptide=27pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=99.7% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1470 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal stroma- degraded peptide=60pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=98.5% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1471 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Corneal stroma- degraded peptide=32pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1472 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Iris-Ciliary Body- degraded peptide=2.2pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1473 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Iris-Ciliary Body- degraded peptide=7.8pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=98.1% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1474 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Tissue: Iris-Ciliary Body- intact peptide=11.9pmoles/g tissue, degraded peptide=5.5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1475 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Fluid: Aqueous humor- degraded peptide=0.7pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1476 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Fluid: Aqueous humor- degraded peptide=2.5pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1477 | Methionine enkephalin | YGGFM | Radioactive determination | Met-enkephalin, also known as metenkefalin is a opioid growth factor, naturally occurring as an endogenous opioid peptide that has opioid effects of a relatively short duration | Fluid: Aqueous humor- degraded peptide=1.75pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=100% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1478 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Fluid: Tears- degraded peptide=4250pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1479 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Fluid: Tears- degraded peptide=950pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=0% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1480 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Conjunctiva- intact peptide=312pmoles/g tissue, degraded peptide=342pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=0.4% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1481 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Conjunctiva- intact peptide=18pmoles/g tissue, degraded peptide=70pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=16.7% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1482 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Conjunctiva- intact peptide=5pmoles/g tissue, degraded peptide=52pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=13% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1483 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal epithelium- degraded peptide=65pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=13.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1484 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal epithelium- intact peptide=30pmoles/g tissue, degraded peptide=75pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=19.2% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1485 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal epithelium- degraded peptide=55pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=24.9% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1486 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal stroma- degraded peptide=7.5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=10.3% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1487 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal stroma- intact peptide=5pmoles/g tissue, degraded peptide=12.5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=22.4% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1488 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Corneal stroma- intact peptide=3pmoles/g tissue, degraded peptide=5pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=34.5% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1489 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Iris-Ciliary Body- intact peptide=0.3pmoles/g tissue, degraded peptide=0.6pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=29.8% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1490 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Iris-Ciliary Body- intact peptide=0.4pmoles/g tissue, degraded peptide=1.25pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=36.1% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1491 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Tissue: Iris-Ciliary Body- intact peptide=0.5pmoles/g tissue, degraded peptide=1.25pmoles/g tissue, Percent of recovered enkephalin attributable to degradation products=42.3% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1492 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Fluid: Aqueous humor- intact peptide=0.25pmoles/ml fluid, degraded peptide=0.8pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=49.6% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1493 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Fluid: Aqueous humor- intact peptide=0.75pmoles/ml fluid, degraded peptide=1.0pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=31.3% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1494 | [D-ala2]-met-enkephalinamide | YaGFM | Radioactive determination | A potent opioid peptide | Fluid: Aqueous humor- intact peptide=0.3pmoles/ml fluid, degraded peptide=0.35pmoles/ml fluid, Percent of recovered enkephalin attributable to degradation products=80.2% | Superior limbus of both eyes of each male, albino New Zealand rabbits | 3503119 |
| 1495 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Serum:55±125ng/ml, Aqueous humor:168±184 and Cornea:432±150ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1496 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Serum:68±100ng/ml, Aqueous humor:46±27 and Cornea:762±330ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1497 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Serum:87±153ng/ml, Aqueous humor:68±49 and Cornea:926±384ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1498 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Serum:75±75ng/ml, Aqueous humor:62±35 and Cornea:557±194ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1499 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Cornea:584±90ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1500 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Negative control- Serum:94±38ng/ml, Aqueous humor:12±21ng/ml, Cornea:38±39ng/ml; Cyclosporine concentration after incubation time- Serum:0±19ng/ml, Aqueous humor:24±12and Cornea:672±275ng/ml | Eyes of New Zealand white rabbits | 3977661 |
| 1501 | Senktide | DF-Me-Phe-GLM | Radioimmunoassay | NK3 tachykinin receptor agonist. Causes direct excitation of dopamine neurons; enhances dopaminergic function. Induces locomotor activity. | The mean maximum pupillary constriction observed with senktide (25 mg, i.v.) was 4.25+0.25 mm. | Eye of rabbit | 9351503 |
| 1502 | Cyclosporine | Aa-MeLeu-MeLeu-MeVal-3-hydroxy-N,4-dimethyl- L-2-amino-6-octenoyl-Abu-MeGly-MeLeu-V-MeLeu | Secretoneurin (SN) is detected in 10-100µl of aqueous humor, aspirated immediately before surgery by radioimmunoassay | Cyclosporine is a neutral, hydrophobic, cyclic and fungal metabolite with potent immunosuppressive activity and novel immunologic potential | Secretoneurin-like immunoreactivities were detectable and averaged 474.24 fmol/ml (±34.4) in the Cy A group. | Human patients(8 eyes) undergoing cataract surgery belonging to 39-91 years of age | 15572199 |
| 1503 | gD 1-29 (group 1) | SKYALVDASLKMADP NRFRGKDLPVLDQL | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Failed to induce significant IgA titers (p > 1). | eye | 15603887 |
| 1504 | gD 22-52 (group 1) | DLPVLQLTDPPGVRRV YHIQAGLPDPFQPPS | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Induced higher IgA response. | eye | 15603887 |
| 1505 | gD 49-82 (group 1) | QPPSLPITVYYAVLERA CRSVLLNAPSEAPQIVR | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Gave lower but significant responses (p <0.05) | eye | 15603887 |
| 1506 | gD 77-104 (group 1) | APQIVRGASEDVRK QPYNLTIAWFRMGG | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Failed to induce significant IgA titers (p > 1). | eye | 15603887 |
| 1507 | gD 96-123 (group 2) | TIAWFRMGGNCAIP ITVMEYTECSYNKS | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Gave lower but significant responses (p <0.05) | eye | 15603887 |
| 1508 | gD 121-152 (group 2) | NKSLGACPIRTQPRWN YYDSFSAVSEDNLGFL | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Gave lower but significant responses (p <0.05) | eye | 15603887 |
| 1509 | gD 146-179 (group 2) | EDNLGFLMHAPAFETAG TYLRLVKINDWTEITQF | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Induced higher IgA response | eye | 15603887 |
| 1510 | gD 176-206 (group 2) | TQFILEHRAKGSCKY ALPLRIPPSACLSPQ | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Induced higher IgA response | eye | 15603887 |
| 1511 | gD 200-234 (group 3) | SACLSPQAYQQGVTV DSIGMLPRFIPENQR TVAVY | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Gave lower but significant responses (p <0.05) | eye | 15603887 |
| 1512 | gD 228-257 (group 3) | QRTVAVYSLKIAGWH GPKAPYTSTLLPPEL | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Induced higher IgA response | eye | 15603887 |
| 1513 | gD 287-317 (group 3) | APQIPPNWHIPSIQDA ATPYHPPATPNNMGL | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Gave lower but significant responses (p <0.05) | eye | 15603887 |
| 1514 | gD 332-358 (group 3) | ICGIVYWMRRHTQKAP KRIRLPHIRED | ELISA, Antibody assay, Peptide specific T-cell assays | not mentioned | Induced higher IgA response | eye | 15603887 |
| 1515 | Nerve Growth Factor | SSSHPIFHRGEFSVCD SVSVWVGDKTTATDIK GKEVMVLGEVNINNSV FKQYFFETKCRDPNPV DSGCRGIDSKHWNSYC TTTHTFVKALTMDGKQ AAWRFIRIDTACVCVL SRKAVRRA | Immunostaining | Neurotrophic and immunomodulatory mediator responsible for the growth, differentiation, and survival of sensory neurons and acceleration of wound healing | The average subbasal tubulin positive nerve bundle area in controls was 0.85. Treatment with NGF produced significant differences with respect to the control (P < 0.05). | Rabbit eye | 16123410 |
| 1516 | Dipeptide Monoester Ganciclovir | VV | HPLC analysis, tissue hydrolysis, 2 way ANOVA | Dipeptide monoester ganciclovir prodrugs with the goal of improving ocular bioavailability of GCV from topical ophthalmic solutions | 10.0 ng/min | cornea of the eye | 16386088 |
| 1525 | L-POD (lissamine- conjugated peptide for ocular delivery) | GGG(ARKKAAKA)4 | Fluorescence-activated cell sorting (FACS), Vital staining with Lissamine | A novel cell-penetrating peptide POD has the ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo. It also acts as a microbicide, potentially providing a safer and more efficacious method of delivering molecules t | L-POD bound strongly to the cornea, sclera and the dura of the optic nerve in vivo. In contrast, lissamine only weakly stained the cornea and sclera and did not stain the dura of the optic nerve. | Cornea of male C57BL/6J mice | 17923842 |
| 1526 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Clinical score: Flagellin treated-2/PBS-6.2, Fungal clearance: Flagellin-3/PBS-0.5CFU(1000) of C. albicans per cornea, Reduced cytokine production and PMN infiltration= MIP-2:Flagellin-0/PBS-75pg/µg protein; ELISA:Flagellin has less content of the protein under study than present in PBS; MPO activity per cornea: Flagellin has less activity as compared to PBS control. | Eyes of wild type C57BL6 mice | 21310913 |
| 1527 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Clinical score: Flagellin treated-1-2/PBS-6-7, Fungal clearance: Flagellin-0/PBS-1.7CFU(1000) of C. albicans per cornea, Reduced cytokine production and PMN infiltration= MIP-2:Flagellin-0/PBS-5pg/µg protein; ELISA:Flagellin has less content of the protein under study than present in PBS; MPO activity per cornea: Flagellin has almost negligible activity as compared to PBS control. | Eyes of wild type C57BL6 mice | 21310913 |
| 1528 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Clinical score: Flagellin treated- ~0/PBS-5.8 | Eyes of wild type C57BL6 mice | 21310913 |
| 1529 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Fungal clearance: Flagellin-2/PBS-6CFU(1000) of C. albicans per cornea, Reduced cytokine production and PMN infiltration= MIP-2:Flagellin-9.5/PBS-7pg/µg protein; ELISA:Flagellin has more content of the protein under study than present in PBS; MPO activity per cornea: Flagellin has more activity as compared to PBS control. | Eyes of wild type C57BL6 mice | 21310913 |
| 1530 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Clinical score of Flagellin is slightly more than PBS control, both approximating to 9.1 and 8.9 respectively. | Eyes of TLR5-/- mouse breeding pairs | 21310913 |
| 1531 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Clinical score: Flagellin-11.1/PBS-10.9; CFU(1000) of C. albicans per cornea-Flagellin-3.4/PBS-4.2; MPO activity per cornea: Flagellin-23/PBS-19. | Eyes of TLR5-/- mouse breeding pairs | 21310913 |
| 1532 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*104 CFU of C. albicans are: Wild type-5.3, KO-9.4 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1533 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*104 CFU of C. albicans are: Wild type-5.8, KO-11.6 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1534 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*104 CFU of C. albicans are: Wild type-2.9, KO-11.8 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1535 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*105 CFU of C. albicans are: Wild type-8.7, KO-9.8 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1536 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*105 CFU of C. albicans are: Wild type-9.3, KO-12 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1537 | Flagellin | ALTVNTNIASLNTQRNLNNS SASLNTSLQRLSTGSRINSAKD DAAGLQIANRLTSQVNGL NVATKNANDGISLAQT AEGALQQSTNILQRMRDL SLQSANGSNSDSERTALN GEVKQLQKELDRISNTTTFGG RKLLDGSFGVASFQVG SAANEIISVGIDEMSAES LNGTYFKADGGGAVTAAT ASGTVDIAIGITGGSAVNV KVDMKGNETAEQAA AKIAAAVNDANVGI GAFSDGDTISY | Fungal load determination, Myeloperoxidase(MPO) determination and Cytokine ELISA measurement | Topical flagellin enhanced innate immunity and protected injured corneas from C. albicans keratitis in a TLR5-dependent manner | Camp-/- mouse corneas were more susceptible than the wild type to C. albicans. Mean clinical scores after infection with 1.0*105 CFU of C. albicans are: Wild type-9.1, KO-11.9 | Eyes of Camp-/- [CRAMP-deficient] mouse breeding pairs on a B6 background | 21310913 |
| 1538 | PEDF (Pigment epithelium-derived factor) | QNPASPPEEGSPDPDSTGA LVEEEDPFFKVPVNKLA AAVSNFGYDLYRVRSSTS PTTNVLLSPLSVATAL SALSLGAEQRTESIIHR ALYYDLISSPDIHGTYKEL LDTVTAPQKNLKSAS RIVFEKKLRIKSSFVAPLE KSYGTRPRVLTGNP RLDLQEINNWVQAQ MKGKLARSTKEIPDEIS ILLLGVAHFKGQWVTKF DSRKTSLEDFYLDEER TVRVPMMSDPKAVLR YGLDSD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | It induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. | Neo-vascularized area= 2% due to PEDF (PBS=3%) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1539 | PEDF (Pigment epithelium-derived factor) | QNPASPPEEGSPDPDSTGA LVEEEDPFFKVPVNKLA AAVSNFGYDLYRVRSSTS PTTNVLLSPLSVATAL SALSLGAEQRTESIIHR ALYYDLISSPDIHGTYKEL LDTVTAPQKNLKSAS RIVFEKKLRIKSSFVAPLE KSYGTRPRVLTGNP RLDLQEINNWVQAQ MKGKLARSTKEIPDEIS ILLLGVAHFKGQWVTKF DSRKTSLEDFYLDEER TVRVPMMSDPKAVLR YGLDSD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | It induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. | Neo-vascularized area= 9% due to PEDF (PBS=10%) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1540 | PEDF (Pigment epithelium-derived factor) | QNPASPPEEGSPDPDSTGA LVEEEDPFFKVPVNKLA AAVSNFGYDLYRVRSSTS PTTNVLLSPLSVATAL SALSLGAEQRTESIIHR ALYYDLISSPDIHGTYKEL LDTVTAPQKNLKSAS RIVFEKKLRIKSSFVAPLE KSYGTRPRVLTGNP RLDLQEINNWVQAQ MKGKLARSTKEIPDEIS ILLLGVAHFKGQWVTKF DSRKTSLEDFYLDEER TVRVPMMSDPKAVLR YGLDSD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | It induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. | Neo-vascularized area= 18% due to PEDF (PBS=20%) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1541 | PEDF (Pigment epithelium-derived factor) | QNPASPPEEGSPDPDSTGA LVEEEDPFFKVPVNKLA AAVSNFGYDLYRVRSSTS PTTNVLLSPLSVATAL SALSLGAEQRTESIIHR ALYYDLISSPDIHGTYKEL LDTVTAPQKNLKSAS RIVFEKKLRIKSSFVAPLE KSYGTRPRVLTGNP RLDLQEINNWVQAQ MKGKLARSTKEIPDEIS ILLLGVAHFKGQWVTKF DSRKTSLEDFYLDEER TVRVPMMSDPKAVLR YGLDSD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | It induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. | Neo-vascularized area= 22% due to PEDF (PBS=31%) or 65% of PBS on day 7(Control=4% of PBS); Oxidative stress generation, 8-OHdG level=75% of PBS (Control=50% of PBS); VEGF expression, VEGF level=71% of PBS (Control=40% of PBS) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1542 | P5-1 (381–387 residue of full-length PEDF protein) | HLTFPLD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | Not mentioned | Neo-vascularized area=82% of PBS on day 7(Control=4% of PBS); Oxidative stress generation, 8-OHdG level=80% of PBS (Control=50% of PBS); VEGF expression, VEGF level=73% of PBS (Control=40% of PBS) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1543 | P5-2 (388–393 residue of full-length PEDF protein) | YHLNQP | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | Not mentioned | Neo-vascularized area=64% of PBS on day 7(Control=4% of PBS); Oxidative stress generation, 8-OHdG level=76% of PBS (Control=50% of PBS); VEGF expression, VEGF level=69% of PBS (Control=40% of PBS) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1544 | P5-3 (394–400 residue of full-length PEDF protein) | FIFVLRD | VEGF and 8-OHdG Immunostaining, Measurement of corneal neo-vascularization via avidin-biotin-alkaline phosphatase kit and statistical analysis | Not mentioned | Neo-vascularized area=65% of PBS on day 7(Control=4% of PBS); Oxidative stress generation, 8-OHdG level=67% of PBS (Control=50% of PBS); VEGF expression, VEGF level=50% of PBS (Control=40% of PBS) | Seven week-old male Spraque–Dawley rat's right eye was used as test and left eye considered as control (PBS) | 22386653 |
| 1545 | μ-N2-10-2 (HIV-Nμ) (μ-calpain peptide ) | GRKKRRQRRRPPQ-P DALKSRTLR | Immunofluorescence,TUNEL staining | Not mentioned | TUNEL positive cells reduced by 50% in HIV-nu traeted retinas | cornea of the eye | 22885154 |
| 1547 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 5.1 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1548 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4.1 Log10 (cfu/ml); Control(PBS):6.4 Log10 (cfu/ml) | Cornea | 24637683 |
| 1549 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4.9 Log10 (cfu/ml); Control(PBS):7.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1550 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1551 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.4 Log10 (cfu/ml) | Cornea | 24637683 |
| 1552 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1553 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1554 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide:2 Log10 (cfu/ml); Control(PBS):6.4 Log10 (cfu/ml) | Cornea | 24637683 |
| 1555 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1556 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4.6 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1557 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4 Log10 (cfu/ml); Control(PBS):6.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1558 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 3.9 Log10 (cfu/ml); Control(PBS):7 Log10 (cfu/ml) | Cornea | 24637683 |
| 1559 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1560 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1561 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7 Log10 (cfu/ml) | Cornea | 24637683 |
| 1562 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml) | Cornea | 24637683 |
| 1563 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1564 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7 Log10 (cfu/ml) | Cornea | 24637683 |
| 1565 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4.8 Log10 (cfu/ml); Control(PBS):5.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1566 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 4.3 Log10 (cfu/ml); Control(PBS):6.2 Log10 (cfu/ml) | Cornea | 24637683 |
| 1567 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 5.2 Log10 (cfu/ml); Control(PBS):7.9 Log10 (cfu/ml) | Cornea | 24637683 |
| 1568 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 3.5 Log10 (cfu/ml); Control(PBS):5.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1569 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.2 Log10 (cfu/ml) | Cornea | 24637683 |
| 1570 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7.9 Log10 (cfu/ml) | Cornea | 24637683 |
| 1571 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):5.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1572 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):6.2 Log10 (cfu/ml) | Cornea | 24637683 |
| 1573 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of peptide: 2 Log10 (cfu/ml); Control(PBS):7.9 Log10 (cfu/ml) | Cornea | 24637683 |
| 1574 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of OH-CATH30:4.4 Log10 (cfu/ml); Control(PBS):6.1 Log10 (cfu/ml); Levofloxacin:5.7 Log10 (cfu/ml); OH-CATH30+Levofloxacin:4.8 Log10 (cfu/ml) | Cornea | 24637683 |
| 1575 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of OH-CATH30:4.2 Log10 (cfu/ml); Control(PBS):6.3 Log10 (cfu/ml); Levofloxacin:5.8 Log10 (cfu/ml); OH-CATH30+Levofloxacin:4.6 Log10 (cfu/ml) | Cornea | 24637683 |
| 1576 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of OH-CATH30:4.8 Log10 (cfu/ml); Control(PBS):7.2 Log10 (cfu/ml); Levofloxacin:6 Log10 (cfu/ml); OH-CATH30+Levofloxacin:4 Log10 (cfu/ml) | Cornea | 24637683 |
| 1577 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of OH-CATH30:6.1 Log10 (cfu/ml); Control(PBS):8.1 Log10 (cfu/ml); Levofloxacin:7.4 Log10 (cfu/ml); OH-CATH30+Levofloxacin:3.5 Log10 (cfu/ml) | Cornea | 24637683 |
| 1578 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Time kill assay of OH-CATH30:7.2 Log10 (cfu/ml); Control(PBS):8.5 Log10 (cfu/ml); Levofloxacin:8 Log10 (cfu/ml); OH-CATH30+Levofloxacin:3.1 Log10 (cfu/ml) | Cornea | 24637683 |
| 1579 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.8; PBS-1.6, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1580 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.8; PBS-2.25, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1581 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.6; PBS-2.85, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1582 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.8; PBS-1.6; Levofloxacin-1.2 ; OH-CATH30+Levofloxacin-0.4, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1583 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.8; PBS-2.25; Levofloxacin-1.4 ; OH-CATH30+Levofloxacin-0.7, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1584 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Mean clinical score: OH-CATH30-0.6; PBS-2.85; Levofloxacin-1.7 ; OH-CATH30+Levofloxacin-0.3, where, 0= clear;1= slight opacity partially or fully covering the pupil;2= slight opacity fully covering the anterior segment;3= dense opacity partially or fully covering the pupil and 4= dense opacity covering the anterior segment and corneal perforation | Cornea | 24637683 |
| 1585 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Bacterial burden: OH-CATH30- 5.7 Log10 CFU/cornea; PBS- 8.1 Log10 CFU/cornea | Cornea | 24637683 |
| 1586 | OH-CATH30 | KFFKKLKNSVKKRAK KFFKKPRVIGVSIPF | Time kill assay, Clinical and histological examination, Measurement of bacterial burden | Cationic peptide of cathelicidin family. Exerts potent antibacterial activity, selective immunomodulatory properties and low toxicity to eukaryotic cells | Bacterial burden: OH-CATH30- 5.7 Log10 CFU/cornea; PBS- 8.1 Log10 CFU/cornea; Levofloxacin- 6.1 Log10 CFU/cornea; Peptide+Levofloxacin- 3.9 Log10 CFU/cornea | Cornea | 24637683 |